

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Application Number	10/531,552
	Filing Date	November 8, 2005
	First Named Inventor	Jerome B. Zeldis
	Art Unit	1627
	Examiner Name	Betton, Timothy E.
	Attorney Docket No.	9516-075-999

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C115	Reza, S. <i>et al.</i> , "Tumor Necrosis Factor- α Levels Decrease with Anticytokine Therapy in Patients with Myelodysplastic Syndromes," <i>Journal of Interferon and Cytokine Research</i> , 1998, 18:871-877	
	C116	Raza, A. <i>et al.</i> , "Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone," <i>Blood</i> , 2000, 95(5):1580-1587	
	C117	Copy of Official Communication in corresponding European Patent Appl. No. 03 726 263.1 dated March 11, 2010	

NY1-4264999v1

**EXAMINER
SIGNATURE**
DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.